L’anticorps Humanized Monoclonal anti-CLDN18.2 (Zolbetuximab Biosimilar) a été validé pour FACS et in vivo. Il convient pour détecter CLDN18.2 (Zolbetuximab Biosimilar) dans des échantillons de Humain.
What is zolbetuximab biosimilar research grade? Zolbetuximab is a humanized monoclonal antibody directed against the human protein Claudin 18.2 (the isoform 2 of Claudin), and potentially used for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. Zolbetuximab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Zolbetuximab biosimilar uses the same protein sequences as the potential therapeutic antibody zolbetuximab . Claudin-18 in humans is a protein encoded by the CLDN18 gene. The CLDN18 protein belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. Isoform 2 (Claudin 18.2) is abundant in gastric tumors.